Marine Non-Glycosaminoglycan Sulfated Glycans as Potential Pharmaceuticals

Pharmaceuticals

Vitor H. Pomin¹  Madalena M. M. Pinto¹  Maria Emília de Sousa¹ 

[1] Program of Glycobiology, Institute of Medical Biochemistry Leopoldo de Meis, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-913, Brazil; E-Mail

关键词: angiogenesis;    cancer;    coagulation;    inflammation;    marine glycans;    microbial infection;    sulfated fucans;    sulfated galactans;    thrombosis;   

DOI  :  10.3390/ph8040848

来源: mdpi

【 摘 要 】

Sulfated fucans (SFs) and sulfated galactans (SGs) are currently the marine non-glycosaminoglycan (GAG) sulfated glycans most studied in glycomics. These compounds exhibit therapeutic effects in several pathophysiological systems such as blood coagulation, thrombosis, neovascularization, cancer, inflammation, and microbial infections. As analogs of the largely employed GAGs and due to some limitations of the GAG-based therapies, SFs and SGs comprise new carbohydrate-based therapeutics available for clinical studies. Here, the principal structural features and the major mechanisms of action of the SFs and SGs in the above-mentioned pathophysiological systems are presented. Discussion is also given on the current challenges and the future perspectives in drug development of these marine glycans.

【 授权许可】

CC BY   
© 2015 by the author; licensee MDPI, Basel, Switzerland.